Safety and Tolerability of a Modified TIMI-14 Protocol in AMI Patients: A Pilot Study
Journal of Clinical and Basic Cardiology 2002; 5 (2): 193-196
PDF Summary
Keywords: akuter Myokardinfarkt, Glykoprotein-IIb-IIIa-Antagonist, TIMI-14-Studie, acute myocardial infarction, GPIIb-IIIa-inhibitors, TIMI-14 trial
Aim of the study was to evaluate the safety and tolerability of a modified combination of thrombolysis plus glycoprotein IIb/IIIa receptor inhibitors in AMI patients versus a TIMI-14 protocol. 132 hospitalised patients within 4 h from onset of symptoms were randomised (double blind) in two groups. Group Immediately (66 patients) received thrombolytic treatment (50 mg rtPA) according to TIMI-14 study and standard treatment with glycoprotein IIb/IIIa receptor inhibitors. Group After (66 patients) received thrombolytic treatment (50 mg rtPA in 30 min) and after 30 min from starting thrombolysis received glycoprotein IIb/IIIa receptor inhibitors. Group Immediately: 51 patients showed rapid reperfusion as confirmed by coronarography performed after 12-72 h. Group After: 60 patients showed rapid reperfusion as confirmed by coronarography after 12-72 h. Side effects were similar in both groups. Patients receiving a modified protocol showed a favourable trend in incidence of reperfusion. Our data suggest the possibility to use a modified protocol and show the feasibility, safety and tolerability of this different protocol in timing of combination of GP IIb/IIIa receptor inhibitors with thrombolysis in patients with AMI. The bleeding risk was similar in both groups. These very preliminary data suggest other and larger studies.
Journal of Clinical and Basic Cardiology 2002; 5 (2): 193-196
PDF Summary
Keywords: akuter Myokardinfarkt, Glykoprotein-IIb-IIIa-Antagonist, TIMI-14-Studie, acute myocardial infarction, GPIIb-IIIa-inhibitors, TIMI-14 trial
Aim of the study was to evaluate the safety and tolerability of a modified combination of thrombolysis plus glycoprotein IIb/IIIa receptor inhibitors in AMI patients versus a TIMI-14 protocol. 132 hospitalised patients within 4 h from onset of symptoms were randomised (double blind) in two groups. Group Immediately (66 patients) received thrombolytic treatment (50 mg rtPA) according to TIMI-14 study and standard treatment with glycoprotein IIb/IIIa receptor inhibitors. Group After (66 patients) received thrombolytic treatment (50 mg rtPA in 30 min) and after 30 min from starting thrombolysis received glycoprotein IIb/IIIa receptor inhibitors. Group Immediately: 51 patients showed rapid reperfusion as confirmed by coronarography performed after 12-72 h. Group After: 60 patients showed rapid reperfusion as confirmed by coronarography after 12-72 h. Side effects were similar in both groups. Patients receiving a modified protocol showed a favourable trend in incidence of reperfusion. Our data suggest the possibility to use a modified protocol and show the feasibility, safety and tolerability of this different protocol in timing of combination of GP IIb/IIIa receptor inhibitors with thrombolysis in patients with AMI. The bleeding risk was similar in both groups. These very preliminary data suggest other and larger studies.